{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:56:15Z","timestamp":1783526175175,"version":"3.55.0"},"publisher-location":"Berlin, Heidelberg","reference-count":94,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642029110","type":"print"},{"value":"9783642029127","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/7854_2009_35","type":"book-chapter","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T15:34:52Z","timestamp":1267716892000},"page":"469-485","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacologic Treatment of Panic Disorder"],"prefix":"10.1007","author":[{"given":"Murray","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,5]]},"reference":[{"issue":"1","key":"35_CR1_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1176\/ajp.153.1.69","volume":"153","author":"JL Abelson","year":"1996","unstructured":"Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry 153(1):69\u201373","journal-title":"Am J Psychiatry"},{"key":"35_CR2_35","volume-title":"Practice guideline for the treatment of persons with disorder","author":"Association American Psychiatric","year":"2009","unstructured":"American Psychiatric Association (2009) Practice guideline for the treatment of persons with disorder, 2nd edn. American Psychiatric Association, Washington, DC","edition":"2"},{"issue":"1","key":"35_CR3_35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","volume":"103","author":"GM Asnis","year":"2001","unstructured":"Asnis GM, Hameedi FA et al (2001) Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 103(1):1\u201314","journal-title":"Psychiatry Res"},{"issue":"19","key":"35_CR4_35","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1001\/jama.283.19.2529","volume":"283","author":"DH Barlow","year":"2000","unstructured":"Barlow DH, Gorman JM et al (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283(19):2529\u20132536","journal-title":"JAMA"},{"issue":"5","key":"35_CR5_35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4088\/JCP.v59n0509e","volume":"59","author":"TR Berigan","year":"1998","unstructured":"Berigan TR, Casas A et al (1998) Nefazodone and the treatment of panic. J Clin Psychiatry 59(5):256\u2013257","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 15","key":"35_CR6_35","first-page":"12","volume":"62","author":"P Blier","year":"2001","unstructured":"Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62(Suppl 15):12\u201327","journal-title":"J Clin Psychiatry"},{"key":"35_CR7_35","first-page":"37","volume":"26","author":"P Blier","year":"2001","unstructured":"Blier P, Abbott FV (2001) Putatuve mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 26:37\u201343","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"35_CR8_35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00004850-199503000-00006","volume":"10","author":"W Boyer","year":"1995","unstructured":"Boyer W (1995) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10(1):45\u201349","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"35_CR9_35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(SICI)1520-6394(1999)10:3<137::AID-DA8>3.0.CO;2-7","volume":"10","author":"A Bystritsky","year":"1999","unstructured":"Bystritsky A, Rosen R et al (1999) Pilot open-label study of nefazodone in panic disorder. Depress Anxiety 10(3):137\u2013139","journal-title":"Depress Anxiety"},{"key":"35_CR10_35","first-page":"275","volume":"51","author":"Canadian Psychiatric Association","year":"2006","unstructured":"Canadian Psychiatric Association (2006) Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 51:275\u2013277","journal-title":"Can J Psychiatry"},{"issue":"2","key":"35_CR11_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10401239909147053","volume":"11","author":"LL Carpenter","year":"1999","unstructured":"Carpenter LL, Leon Z et al (1999) Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 11(2):81\u201386","journal-title":"Ann Clin Psychiatry"},{"key":"35_CR12_35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1192\/bjp.167.5.635","volume":"167","author":"J Cottraux","year":"1995","unstructured":"Cottraux J, Note ID et al (1995) A controlled study of congnitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 167:635\u2013641","journal-title":"Br J Psychiatry"},{"issue":"5","key":"35_CR13_35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00004714-199610000-00003","volume":"16","author":"NJ Coupland","year":"1996","unstructured":"Coupland NJ, Bell CJ et al (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16(5):356\u2013362","journal-title":"J Clin Psychopharmacol"},{"key":"35_CR14_35","unstructured":"Cross-National and S. Group (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators [published erratum appears in Br J Psychiatry 1992 Nov;161:724] [see comments]. Br J Psychiatry 160:191\u2013202; discussion 202\u2013205"},{"issue":"Suppl 1","key":"35_CR15_35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0022-3956(93)90023-U","volume":"27","author":"CG Curtis","year":"1993","unstructured":"Curtis CG, Massana J et al (1993) Maintenance drug therapy of panic disorder. J Psychiatr Res 27(Suppl 1):127\u2013142","journal-title":"J Psychiatr Res"},{"key":"35_CR16_35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/10401239209150457","volume":"4","author":"SR Dager","year":"1992","unstructured":"Dager SR, Roy-Byrne P et al (1992) Long-term outcome of panic states during double-blind treatment and after withdrawal of aprazolam and placebo. Ann Clin Psychiatry 4:251\u2013258","journal-title":"Ann Clin Psychiatry"},{"issue":"7","key":"35_CR17_35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/hup.421","volume":"17","author":"PN Dannon","year":"2002","unstructured":"Dannon PN, Iancu I et al (2002) The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17(7):329\u2013333","journal-title":"Hum Psychopharmacol"},{"issue":"Suppl 4","key":"35_CR18_35","first-page":"14","volume":"67","author":"M Fava","year":"2006","unstructured":"Fava M (2006) Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 67(Suppl 4):14\u201321","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"35_CR19_35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1345\/aph.1A161","volume":"36","author":"AA Fisher","year":"2002","unstructured":"Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 36(1):67\u201371","journal-title":"Ann Pharmacother"},{"key":"35_CR20_35","first-page":"57","volume-title":"Panic disorder and its treatment","author":"AW Goddard","year":"1998","unstructured":"Goddard AW, Gorman JM et al (1998) Neurobiology of panic disorder. In: Rosenbaum J, Pollack M (eds) Panic disorder and its treatment. Marcel Dekker, Inc, New York, pp 57\u201392"},{"issue":"7","key":"35_CR21_35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.58.7.681","volume":"58","author":"AW Goddard","year":"2001","unstructured":"Goddard AW, Brouette T et al (2001) Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58(7):681\u2013686","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 4","key":"35_CR22_35","first-page":"33","volume":"60","author":"JM Gorman","year":"1999","unstructured":"Gorman JM, Kent JM (1999) SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(Suppl 4):33\u201338, discussion 39","journal-title":"J Clin Psychiatry"},{"key":"35_CR23_35","doi-asserted-by":"crossref","unstructured":"Haas CK, Shekhar A et al (2009) Anxiety Drug Therapy. Encyclopedia of Neuroscience 499\u2013508","DOI":"10.1016\/B978-008045046-9.00377-6"},{"key":"35_CR24_35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/00004714-200010000-00011","volume":"20","author":"D Hirschmann","year":"2000","unstructured":"Hirschmann D, Dannon PN et al (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 20:556\u2013559","journal-title":"J Clin Psychopharmacol"},{"key":"35_CR25_35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/da.20050","volume":"21","author":"M Hollifield","year":"2005","unstructured":"Hollifield M, Thompson PM et al (2005) Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 21:33\u201340","journal-title":"Depress Anxiety"},{"issue":"6","key":"35_CR26_35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00004714-199612000-00003","volume":"16","author":"RH Howland","year":"1996","unstructured":"Howland RH (1996) Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 16(6):425\u2013427","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 2","key":"35_CR27_35","first-page":"20","volume":"58","author":"JW Jefferson","year":"1997","unstructured":"Jefferson JW (1997) Antidepressants in panic disorder. J Clin Psychiatry 58(Suppl 2):20\u201324, discussion 24\u201325","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"35_CR28_35","first-page":"50","volume":"62","author":"JW Jefferson","year":"2001","unstructured":"Jefferson JW (2001) Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry 62(Suppl 1):50\u201353","journal-title":"J Clin Psychiatry"},{"key":"35_CR29_35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nm.2075","volume":"16","author":"PL Johnson","year":"2009","unstructured":"Johnson PL, Truitt W et al (2009) A key role for orexin in panic anxiety. Nat Med 16:111\u2013115","journal-title":"Nat Med"},{"key":"35_CR30_35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","volume":"51","author":"RC Kessler","year":"1994","unstructured":"Kessler RC, McGonagle KA et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8\u201319","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"35_CR31_35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0025-7125(05)70329-1","volume":"85","author":"JH Krystal","year":"2001","unstructured":"Krystal JH, D'Souza DC et al (2001) Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med Clin North Am 85(3):559\u2013577","journal-title":"Med Clin North Am"},{"issue":"1","key":"35_CR32_35","first-page":"25","volume":"25","author":"E Leinonen","year":"2000","unstructured":"Leinonen E, Lepola U et al (2000a) Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25(1):25\u201332","journal-title":"J Psychiatry Neurosci"},{"key":"35_CR33_35","first-page":"24","volume":"25","author":"E Leinonen","year":"2000","unstructured":"Leinonen E, Lepola U et al (2000b) Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25:24\u201332","journal-title":"J Psychiatry Neurosci"},{"key":"35_CR34_35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-0447.1990.tb05321.x","volume":"360","author":"MR Liebowitz","year":"1990","unstructured":"Liebowitz MR, Hollander E et al (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand Suppl 360:29\u201334","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"35_CR35_35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/bjp.173.1.54","volume":"173","author":"PD Londborg","year":"1998","unstructured":"Londborg PD, Wolkow R et al (1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54\u201360","journal-title":"Br J Psychiatry"},{"key":"35_CR36_35","first-page":"435","volume":"54","author":"AK Louie","year":"1993","unstructured":"Louie AK, Lewis TB et al (1993) Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 54:435\u2013438","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"35_CR37_35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00023210-200317030-00001","volume":"17","author":"D Mancama","year":"2003","unstructured":"Mancama D, Kerwin RW (2003) Role of pharmacogenomics in individualizing treatment with SSRI\u2019s. CNS Drugs 17(3):143\u2013151","journal-title":"CNS Drugs"},{"issue":"2","key":"35_CR38_35","first-page":"171","volume":"30","author":"MR Mavissakalian","year":"1994","unstructured":"Mavissakalian MR, Perel JM (1994) Dose-response characterization of the antipanic effects of imipramine. Psychopharmacol Bull 30(2):171\u2013174","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"35_CR39_35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/10401230109148949","volume":"13","author":"MR Mavissakalian","year":"2001","unstructured":"Mavissakalian MR, Perel JM (2001) 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry 13(2):63\u201367","journal-title":"Ann Clin Psychiatry"},{"key":"35_CR40_35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.psc.2009.05.005","volume":"32","author":"RK McHugh","year":"2009","unstructured":"McHugh RK, Smits JAJ et al (2009) Empirically supported treatments for panic disorder. Psychiatr Clin North Am 32:593\u2013610","journal-title":"Psychiatr Clin North Am"},{"key":"35_CR41_35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1192\/bjp.179.6.514","volume":"179","author":"D Michelson","year":"2001","unstructured":"Michelson D, Allgulander C et al (2001) Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179:514\u2013518","journal-title":"Br J Psychiatry"},{"issue":"626\u2013628","key":"35_CR42_35","first-page":"631","volume":"46","author":"S Misri","year":"2000","unstructured":"Misri S, Burgmann A et al (2000) Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician 46(626\u2013628):631\u2013633","journal-title":"Can Fam Physician"},{"key":"35_CR43_35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4088\/JCP.v60n0907","volume":"60","author":"G Moroz","year":"1999","unstructured":"Moroz G, Rosenbaum JF (1999) Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 60:604\u2013612","journal-title":"J Clin Psychiatry"},{"key":"35_CR44_35","first-page":"22","volume":"9","author":"DJ Munjack","year":"1989","unstructured":"Munjack DJ, Crocker B et al (1989) Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 9:22\u201327","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 2","key":"35_CR45_35","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1097\/00004850-200008002-00008","volume":"15","author":"TK Murphy","year":"2000","unstructured":"Murphy TK, Bengtson MA et al (2000) Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int Clin Psychopharmacol 15(Suppl 2):S47\u2013S63","journal-title":"Int Clin Psychopharmacol"},{"key":"35_CR46_35","first-page":"349","volume":"57","author":"R Noyes","year":"1996","unstructured":"Noyes R, Burrows GD et al (1996) Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 57:349\u2013355","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"35_CR47_35","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1176\/appi.ajp.158.12.1989","volume":"158","author":"MW Otto","year":"2001","unstructured":"Otto MW, Tuby KS et al (2001) An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158(12):1989\u20131992","journal-title":"Am J Psychiatry"},{"key":"35_CR48_35","unstructured":"Otto MW, Tolin DF et al (in press) Efficacy of d-cycloserine for enhancing response to cognitive behavioral therapy for panic disorder. Biol Psychiatry"},{"key":"35_CR49_35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","volume":"20","author":"AC Pande","year":"2000","unstructured":"Pande AC, Pollack MH et al (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467\u2013471","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"35_CR50_35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-2001-14283","volume":"34","author":"G Perna","year":"2001","unstructured":"Perna G, Bertani A et al (2001) A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 34(3):85\u201390","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"35_CR51_35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0006-3223(01)01279-3","volume":"51","author":"RK Pitman","year":"2002","unstructured":"Pitman RK, Sanders KM et al (2002) Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51(2):189\u2013192","journal-title":"Biol Psychiatry"},{"key":"35_CR52_35","first-page":"971","volume-title":"Psychopharmacology: the fourth generation of progress","author":"P Plotsky","year":"1995","unstructured":"Plotsky P, Owens M et al (1995) Neuropeptide alterations in mood disorders. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 971\u2013982"},{"issue":"9","key":"35_CR53_35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/ajp.155.9.1189","volume":"155","author":"RB Pohl","year":"1998","unstructured":"Pohl RB, Wolkow RM et al (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155(9):1189\u20131195","journal-title":"Am J Psychiatry"},{"issue":"Suppl 11","key":"35_CR54_35","first-page":"19","volume":"58","author":"MH Pollack","year":"1997","unstructured":"Pollack MH, Worthington JJ et al (1997) Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 58(Suppl 11):19\u201323","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"35_CR55_35","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","volume":"55","author":"MH Pollack","year":"1998","unstructured":"Pollack MH, Otto MW et al (1998) Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55(11):1010\u20131016","journal-title":"Arch Gen Psychiatry"},{"key":"35_CR56_35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/02698811030173009","volume":"17","author":"MH Pollack","year":"2003","unstructured":"Pollack MH, Simon NM et al (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17:276\u2013282","journal-title":"J Psychopharmacol"},{"issue":"4","key":"35_CR57_35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1034\/j.1600-0447.2001.00263.x","volume":"104","author":"MH Rapaport","year":"2001","unstructured":"Rapaport MH, Wolkow R et al (2001) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104(4):289\u2013298","journal-title":"Acta Psychiatr Scand"},{"key":"35_CR58_35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00004714-199112000-00003","volume":"11","author":"CL Ravaris","year":"1991","unstructured":"Ravaris CL, Friedman MJ et al (1991) A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol 11:344\u2013350","journal-title":"J Clin Psychopharmacol"},{"key":"35_CR59_35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/400_2007_051","volume":"46","author":"RK Reinscheid","year":"2008","unstructured":"Reinscheid RK (2008) Neuropeptide S: anatomy, pharmacology, genetics and physiological functions. Results Probl Cell Differ 46:145\u2013158","journal-title":"Results Probl Cell Differ"},{"issue":"5","key":"35_CR60_35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000126788","volume":"60","author":"JM Reul","year":"1994","unstructured":"Reul JM, Labeur MS et al (1994) Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60(5):509\u2013519","journal-title":"Neuroendocrinology"},{"key":"35_CR61_35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archpsyc.1984.01790210031005","volume":"41","author":"LN Robins","year":"1984","unstructured":"Robins LN, Helzer JE et al (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949\u2013958","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl A","key":"35_CR62_35","first-page":"A54","volume":"60","author":"JF Rosenbaum","year":"1996","unstructured":"Rosenbaum JF, Pollock RA et al (1996) The pharmacotherapy of panic disorder. Bull Menninger Clin 60(Suppl A):A54\u2013A75","journal-title":"Bull Menninger Clin"},{"issue":"1","key":"35_CR63_35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1176\/appi.ajp.159.1.23","volume":"159","author":"A Rotondo","year":"2002","unstructured":"Rotondo A, Mazzanti C et al (2002) Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 159(1):23\u201329","journal-title":"Am J Psychiatry"},{"key":"35_CR64_35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1440-1614.2003.01254.x","volume":"37","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2003","unstructured":"Royal Australian and New Zealand College of Psychiatrists (2003) Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 37:641\u2013656","journal-title":"Aust N Z J Psychiatry"},{"issue":"9","key":"35_CR65_35","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4088\/JCP.v62n0903","volume":"62","author":"PP Roy-Byrne","year":"2001","unstructured":"Roy-Byrne PP, Clary CM et al (2001) The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry 62(9):678\u2013682","journal-title":"J Clin Psychiatry"},{"key":"35_CR66_35","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(06)69418-X","volume":"368","author":"PP Roy-Byrne","year":"2006","unstructured":"Roy-Byrne PP, Craske MG, Stein MB (2006) Panic disorder. Lancet 368:1023\u20131032","journal-title":"Lancet"},{"key":"35_CR67_35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.1175055","volume":"325","author":"R Rupprecht","year":"2009","unstructured":"Rupprecht R, Rammes G et al (2009) Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325:490\u2013493","journal-title":"Science"},{"key":"35_CR68_35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1185\/03007999009111500","volume":"12","author":"F Savoldi","year":"1990","unstructured":"Savoldi F, Somenzini G et al (1990) Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Curr Med Res Opin 12:185\u2013190","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"35_CR69_35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00008877-199903000-00002","volume":"10","author":"U Schmitt","year":"1999","unstructured":"Schmitt U, Hiemke C (1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 10(2):131\u2013137","journal-title":"Behav Pharmacol"},{"key":"35_CR70_35","first-page":"19","volume":"53","author":"E Schweizer","year":"1992","unstructured":"Schweizer E, Clary C et al (1992) The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. J Clin Psychiatry 53:19\u201322","journal-title":"J Clin Psychiatry"},{"key":"35_CR71_35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","volume":"50","author":"E Schweizer","year":"1993","unstructured":"Schweizer E, Rickels K et al (1993) Maintenance drug treatment of panic disorder: I. results of a prospective, placebo-controlled comparison of aprazolam and Imipramine. Arch Gen Psychiatry 50:51\u201360","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"35_CR72_35","first-page":"828","volume":"2","author":"I Selak","year":"2001","unstructured":"Selak I (2001) Pregabalin (Pfizer). Curr Opin Invest Drugs 2(6):828\u2013834","journal-title":"Curr Opin Invest Drugs"},{"key":"35_CR73_35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1993.tb03405.x","volume":"88","author":"DV Sheehan","year":"1993","unstructured":"Sheehan DV, Raj AB et al (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 88:1\u201311","journal-title":"Acta Psychiatr Scand"},{"key":"35_CR74_35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00004850-200015060-00004","volume":"15","author":"JI Sheikh","year":"2000","unstructured":"Sheikh JI, Lonborg P et al (2000) The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol 15:335\u2013342","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"35_CR75_35","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0028-3908(99)00215-4","volume":"39","author":"A Shekhar","year":"2000","unstructured":"Shekhar A, Keim SR (2000) LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39(7):1139\u20131146","journal-title":"Neuropharmacology"},{"issue":"Suppl 4","key":"35_CR76_35","first-page":"3","volume":"67","author":"RC Shelton","year":"2006","unstructured":"Shelton RC (2006) The nature of discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 67(Suppl 4):3\u20137","journal-title":"J Clin Psychiatry"},{"key":"35_CR77_35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4088\/JCP.v67n0307","volume":"67","author":"NM Simon","year":"2006","unstructured":"Simon NM, Hoge EA et al (2006) An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381\u2013385","journal-title":"J Clin Psychiatry"},{"key":"35_CR78_35","volume-title":"Comprehensive textbook of psychiatry","author":"MB Stein","year":"2005","unstructured":"Stein MB (2005) Anxiety disorders: somatic treatment. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry. Lippincott, Williams, & Wilkins, Philadelphia, PA"},{"issue":"10","key":"35_CR79_35","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","volume":"158","author":"MB Stein","year":"2001","unstructured":"Stein MB, Sareen J et al (2001) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158(10):1725\u20131727","journal-title":"Am J Psychiatry"},{"issue":"10","key":"35_CR80_35","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1176\/appi.ajp.159.10.1777","volume":"159","author":"MB Stein","year":"2002","unstructured":"Stein MB, Kline NA et al (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 159(10):1777\u20131779","journal-title":"Am J Psychiatry"},{"issue":"8","key":"35_CR81_35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0006-3223(01)01260-4","volume":"50","author":"ST Szabo","year":"2001","unstructured":"Szabo ST, Blier P (2001) Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 50(8):644\u2013646","journal-title":"Biol Psychiatry"},{"issue":"1","key":"35_CR82_35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145700001772","volume":"3","author":"ST Szabo","year":"2000","unstructured":"Szabo ST, de Montigny C et al (2000) Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 3(1):1\u201311","journal-title":"Int J Neuropsychopharmacol"},{"key":"35_CR83_35","first-page":"69","volume":"52","author":"GE Tesar","year":"1991","unstructured":"Tesar GE, Rosenbaum JF et al (1991) Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 52:69\u201376","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"35_CR84_35","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1007\/PL00014164","volume":"249","author":"JW Tiller","year":"1999","unstructured":"Tiller JW, Bouwer C et al (1999) Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249(Suppl 1):S7\u2013S10","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"35_CR85_35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00702-009-0229-6","volume":"116","author":"AK Tiwari","year":"2009","unstructured":"Tiwari AK, Souza RP et al (2009) Pharmacogenetics of anxiolytic drugs. J Neural Transm 116:667\u2013677","journal-title":"J Neural Transm"},{"issue":"5","key":"35_CR86_35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/00004714-199710000-00006","volume":"17","author":"P Tucker","year":"1997","unstructured":"Tucker P, Adamson P et al (1997) Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol 17(5):370\u2013376","journal-title":"J Clin Psychopharmacol"},{"key":"35_CR87_35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/S1516-31802003000200009","volume":"121","author":"AM Valenca","year":"2003","unstructured":"Valenca AM, Nardi AE et al (2003) Therapeutic response to benzodiazepine in panic disorder subtypes. Sao Paulo Med J 121:77\u201380","journal-title":"Sao Paulo Med J"},{"issue":"4","key":"35_CR88_35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/BF02244898","volume":"112","author":"IM Vliet van","year":"1993","unstructured":"van Vliet IM, Westenberg HG et al (1993) MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl) 112(4):483\u2013489","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"35_CR89_35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4088\/JCP.v63n0107","volume":"63","author":"M Versiani","year":"2002","unstructured":"Versiani M, Cassano G et al (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63(1):31\u201337","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"35_CR90_35","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","volume":"22","author":"DL Walker","year":"2002","unstructured":"Walker DL, Ressler KJ et al (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22(6):2343\u20132351","journal-title":"J Neurosci"},{"issue":"7","key":"35_CR91_35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archpedi.156.7.696","volume":"156","author":"N Weintrob","year":"2002","unstructured":"Weintrob N, Cohen D et al (2002) Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156(7):696\u2013701","journal-title":"Arch Pediatr Adolesc Med"},{"key":"35_CR92_35","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1176\/ajp.147.11.1504","volume":"147","author":"MM Weissman","year":"1990","unstructured":"Weissman MM, Markowitz JS et al (1990) Panic disorder and cardiovascular\/cerebrovascular problems: results from a community survey [see comments]. Am J Psychiatry 147:1504\u20131508","journal-title":"Am J Psychiatry"},{"key":"35_CR93_35","first-page":"134","volume":"55","author":"CL Woodman","year":"1994","unstructured":"Woodman CL, Noyes R Jr (1994) Panic disorder: treatment with valproate. J Clin Psychiatry 55:134\u2013136","journal-title":"J Clin Psychiatry"},{"key":"35_CR94_35","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.psyneuen.2009.04.017","volume":"34","author":"P Zwanzger","year":"2009","unstructured":"Zwanzger P, Eser D et al (2009) Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3\u03ac, 5\u03ac-tetrahydrodeoxycorticosterone concentrations. Psychoneuroendocrinology 34:1586\u20131589","journal-title":"Psychoneuroendocrinology"}],"container-title":["Current Topics in Behavioral Neurosciences","Behavioral Neurobiology of Anxiety and Its Treatment"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2009_35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T17:39:18Z","timestamp":1552412358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/7854_2009_35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"ISBN":["9783642029110","9783642029127"],"references-count":94,"URL":"https:\/\/doi.org\/10.1007\/7854_2009_35","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}